Deals
Takeda Expands Cancer Business With $4.66 Billion Ariad Deal
- Deal adds blood cancer pill, experimental lung-cancer drug
- Takeda to pay 75 percent premium; Ariad shares surge Monday
Takeda Acquires Ariad in $4.66B Deal
This article is for subscribers only.
Takeda Pharmaceutical Co. will expand its footprint in the U.S. oncology market with the $4.66 billion purchase of Ariad Pharmaceuticals Inc., adding one potential blockbuster in lung cancer and another already on-the-market therapy.
Takeda will pay $24 a share for Ariad, the companies said in a statement Monday, 75 percent more than its Friday close of $13.74. The deal will give it Ariad’s drug brigatinib, an experimental therapy being tested in lung cancer, and Iclusig, which is estimated to have brought in $170.5 million in 2016.